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Nucleosomes, the fundamental building blocks of eukaryotic chromatin, undergo post-synthetic modiﬁ-
cations and play a major role in the regulation of transcriptional processes. Combinations of these
modiﬁcations, including methylation, regulate chromatin structure, determining its different functional
states and playing a central role in differentiation. The biological signiﬁcance of cellular methylation, par-
ticularly on chromatin, is widely recognized, yet we know little about the mechanisms that link biological
methylation events. To characterize and fully understand protein methylation, we describe here novel
N-mustard analogs of S-adenosyl-L-methionine (SAM) as biochemical tools to better understand protein
arginine methylation events using protein arginine methyltransferase 1 (PRMT1). Speciﬁcally, azide- and
alkyne-functionalized N-mustard analogs serve as cofactor mimics of SAM and are enzymatically trans-
ferred to a model peptide substrate in a PRMT1-dependent fashion. Once incorporated, the resulting alky-
nes and azides can be modiﬁed through chemoselective ligations, including click chemistry and the
Staudinger ligation. These results readily demonstrate the feasibility of utilizing N-mustard analogs as
biochemical tools to site-speciﬁcally label substrates of PRMT1 and serve as an alternative approach to
study protein methylation events.
 2015 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Post-translational modiﬁcations of proteins play a key role in
essentially all cellular processes. Each modiﬁcation is responsible
for very speciﬁc interactions that individually or cumulatively
determine the fate of many regulatory pathways. Speciﬁcally,
methylation of the N-terminus of histone tails is reported to affect
both the conformation of chromatin and the ability of neighboring
genes to activate transcription.1 Methylation is tightly regulated
and very important for normal cellular function; however, anoma-
lous methylation has been linked to a variety of human diseases
including cancer, obesity, immune responses, and neurological dis-
orders.1–4 While the biological signiﬁcance of cellular methylation,
particularly on chromatin, is widely recognized, protein methyla-
tion events are still not completely understood and the possibility
exists of methylated protein substrates yet to be discovered.5–7
Identifying the sites of methylation has proven to be challeng-
ing, as methylated proteins do not contain any inherent chemical
reactivity that could be exploited for detection. Incorporation of
measurable entities, such as a radioactive [3H]-methyl, or a conju-
gated substituent, as generated using Edman degradation, havebeen used.6 However, these techniques are very laborious, requir-
ing multiple stages of preparation prior to analysis. While methyl-
speciﬁc antibodies can be generated to detect sites of methylation
in proteins, these antibodies are generated for a speciﬁc target and
cannot be used universally. With recent advances in mass spec-
trometry technologies, sites of methylation can be characterized
through isotope-labeled methionine in vivo,6 but this technique
lacks the generality needed for the detection of methylation sites
afforded by protein methyltransferases and any function beyond
detection. Interestingly, recent advances in developing new
methodologies to identify protein methylation indicate that ana-
logs of the biological methyl donor S-adenosyl-L-methionine
(SAM) functionalized at either a sulfur or selenium center can label
substrates in an enzyme-dependent fashion.8–11 The success of
such analogs typically requires engineering the SAM binding
pocket of the protein methyltransferase to accommodate addi-
tional functionality.8–10
The need for a more general approach of detecting sites of pro-
tein methylation which utilize native cellular methyltransferases
led to the development of cofactor mimics of SAM. The retention
of key structural components of SAM is essential for obtaining
cofactor mimics which exploit the natural mechanism by which
proteins are methylated,12–15 while containing an N-mustard reac-
tive functionality for effective substrate labeling. Speciﬁcally, the
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tive aziridinium ring at physiological pH upon elimination of
iodide. This positively charged moiety is targeted to the substrate
nucleophilic residue via the protein methyltransferase, initiating
ring-opening and subsequent covalent modiﬁcation. The utility of
1 was previously demonstrated to be enzymatically incorporated
to a 21-residue peptide based on the N-terminus of histone H4
(AcH4-21), as shown in Figure 1,16 which is preferentially methy-
lated by protein arginine methyltransferase 1 (PRMT1).17 In this
work, the use of PRMT1 as the model protein methyltransferase
was continued, as it is the most prevalent PRMT found in eukary-
otes and is responsible for over 85% of PRMT activity in the cell.18
Although the utility of 1 has been demonstrated, it lacks addi-
tional chemical functionality that would facilitate in the isolation
or identiﬁcation of analog-modiﬁed targets through chemoselec-
tive ligations. To identify possible sites of modifying 1 to incorpo-
rate such functionality, analysis of the co-crystal structure of SAM
bound to PRMT1 (1OR8.pdb) suggests that substitutions at the C8
and N6 position of the adenine base extend out of the enzyme
active site and would likely not interfere with PRMT1 binding.19
To follow up this ﬁnding and to further advance the utility of N-
mustard analogs of SAM as biochemical tools of PRMT1, we present
here the analysis of C8- and N6-functionalized analogs of SAM con-
taining azides and alkynes (2–9) shown in Figure 2. Speciﬁcally, the
ability of 2–9 to undergo PRMT1-dependent transfer to AcH4-21
peptide and subsequently biotinylated through click chemistry
and the Staudinger ligation is examined.20,21N
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Figure 2. N-Mustard analogs functiona2. Results and discussion
Initial experiments were carried out to develop Orbitrap tune
methods and ensure enzyme viability using AcH4-21 peptide and
peptide modiﬁed by both SAM and N-mustard analog 1.16 Due to
the hydrophilic nature of AcH4-21, analysis by LC–ESI MS was dif-
ﬁcult, as the peptide did not adhere well to C18 and ion suppres-
sion was evident due to buffer components failing to resolve
from peptide.22,23 Mass spectra obtained without de-salting reac-
tion samples provided adequate conﬁrmation of product formation
despite some degree of ion suppression and salt adducts by 4-(2-
hydroxyethyl)-1-piperazineethanesulfonic acid (HEPES) and NaCl
present in the reaction buffer. Additionally, the high number of
basic residues contained in AcH4-21 peptide generated multiple
charge states ranging from [M+H]+ to [M+7H]7+, where the +4,
+5, and +6 species were most abundant (Supplemental Fig. S1).
Observation of product formation in these charge states was used
as the standard for further analysis. Reactions carried out with
AcH4-21 peptide and SAM indicated that PRMT1 effectively cat-
alyzed the formation of dimethylated peptide, as expected
(Supplemental Fig. S2). Additionally, the desired reaction product
of peptide and 1 was observed in the presence of PRMT1
(Supplemental Fig. S3), conﬁrming previous studies.16
Once transfer of SAM and 1 to peptide was established, C8-sub-
stituted analogs 2–4 were evaluated. Aryl azide 4 was successfully
transferred to peptide in low relative abundance when compared
to the remaining unmodiﬁed peptide, whereas reaction in theN
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Figure 3. LC-ESI MS spectra and expected masses of (A) 4-modiﬁed AcH4-21 peptide and (B) 9-modiﬁed AcH4-21 peptide. Product peaks are denoted by an asterisk ( ) and
agree with expected masses at the most abundant charge states. Additional major peaks were identiﬁed as unmodiﬁed peptide and denoted by a diamond ( ).
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(Supplemental Fig. S4). This conﬁrms that peptide modiﬁcation
by the N-mustard analog 4 is methyltransferase-dependent, as
demonstrated previously.16 Analysis of reactions with alkyl ana-
logs 2 and 3 generated no detectable product as judged by mass
spectrometry. These results were conﬁrmed using MALDI-TOF
MS (data not shown). Although it was hypothesized that the bulk-
ier nature of 2 and 3may have restricted binding within the PRMT1
active site, greater suspicions were of the reaction buffer (HEPES
pH 8.0, NaCl, EDTA, and dithiothreitol, DTT) and alternative compo-
nent concentrations were examined. It was determined that the
PRMT1 storage buffer contained a sufﬁcient concentration of DTT
(0.1 mM ﬁnal) to maintain PRMT1 in its active conformation, thus
allowing for its omission from the reaction buffer. Experiments
with analogs 2–4 were repeated using the DTT-deﬁcient reaction
buffer and results indicated a substantial increase in product for-
mation by mass spectrometry, based on relative abundance. The
desired m/z values for peptide modiﬁed by both 2 and 3 were
observed (Supplemental Figs. S7 and S8, respectively), as well as
the substantial increase in relative abundance for peptide modiﬁed
with 4, compared to unmodiﬁed peptide (Fig. 3A). Quantiﬁcation of
peptide products was not conducted,24,25 as preparing analog-
modiﬁed peptide standards were not synthetically feasible.
Alternative quantiﬁcation methods using deuterated analogs are
being explored for future studies.16 Although quantiﬁcation was
not conducted, it is evident, based on relative abundance, peptides
modiﬁed by 2 and 3 were formed in lower detectable yields com-
pared to peptide modiﬁed by 4. These observations may beattributed to the increase in size of the alkyne and azide side chains
relative to the azide directly attached to the adenosine base. Based
on these results, substitutions at the C8 position of the N-mustard
SAM analogs are accomodated in the PRMT1 active site.
Additionally, it was concluded that all future PRMT1 reactions with
the N-mustard SAM analogs should be conducted in reaction buffer
lacking DTT, as it may improve product formation.
After demonstrating the ability of the C8-substituted N-mustard
analogs to be accomodated in the active site of PRMT1, we next
moved to evaluate substitution at the N6-position using 5–9 and
the optimized reaction buffer lacking DTT. Analysis of PRMT1 reac-
tions with azides 5 and 6 indicated successful transfer to AcH4-21
peptide substrate (Supplemental Figs. S9 and S10, respectively), as
well as with alkynes 7–9 (Supplemental Figs. S11, S12, and 3B,
respectively). Analysis of the relative abundances of the resulting
products indicated that peptide modiﬁed by 5, 6 and 9 were
formed in higher detectable yields compared to peptides modiﬁed
by 7 and 8. Additionally, it is interesting to note while the peptide
modiﬁed with alkyne 9 was detected in reactions employing the
original buffer, the success of analogs 5–8 in modifying peptide
required the DTT-deﬁcient buffer. This ﬁnding conﬁrms that reduc-
ing the concentration of DTT from the reaction improves the for-
mation of the desired peptide products.
With successful transfer of C8- and N6-substituted analogs to
AcH4-21 peptide, the utility of the azide- and alkyne-functional-
ized peptides to undergo further functionalization through
chemoselective ligations was investigated. Additionally, these
studies provided validation that the resulting azide and alkyne
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Figure 4. Structures of biotin-azide 10, biotin-alkyne 11, and biotin-phosphine 12.
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studies focused on biotinylating peptides using well-established
click chemistry methodologies.21 Critical to the success of this
reaction was the alleviation of the resulting peptide-PRMT1 com-
plex through brief heat denaturation prior to addition of either bio-
tin-azide (10) or biotin-alkyne (11) (Fig. 4), precomplexed
CuSO4tris(benzyltriazolylmethyl)amine (TBTA), and sodiumFigure 5. LC–ESI MS spectra and expected masses for the chemoselective ligations of
denoted by an asterisk ( ) and agree with expected masses at the most abundant chargascorbate. Results obtained from the biotin ligation to peptides
modiﬁed by 2–9 varied. Analysis of the biotinylation reactions with
the alkynylated peptides indicated that the only successful cou-
pling occurred with 9-modiﬁed peptide, as it was detected across
multiple charge states (Fig. 5A). All remaining alkyne-functional-
ized peptides failed to produce evidence of biotinylated products.
Analysis of the azidated peptides indicated that successful biotin
coupling occurred with 5- and 6-modiﬁed peptides only
(Supplemental Figs. S17 and S18, respectively), while the other
azide-modiﬁed peptides failed to produce detectable biotin-la-
beled products. Failed biotinylation reactions can be rationalized
by literature which indicates that low levels of substrate undergo-
ing click chemistry suffer from inefﬁcient coupling and often
require a large excess of reagents to facilitate the reaction.26 This
ﬁnding is consistent with the inability of 2-, 3-, 7-, and 8-modiﬁed
peptides to undergo click chemistry, as these products correlate to
observed lower relative abundances, compared to unmodiﬁed pep-
tide, following the methyltransferase reaction. Additional ligations
were attempted to subject these azide- and alkyne-functionalized
peptides to increased concentrations of coupling components,
but still failed to generate the desired biotinylated peptides.
However, coupling to biotin readily occurred with the free analog
remaining in solution, indicating that the integrity of the azide
and alkyne was maintained. Finally, experiments were carried
out to biotinylate 4-modiﬁed peptide via the Staudinger ligation
with biotin-phosphine 12.27 It is important to note that the result-
ing linkage from the coupling of the aryl-azide does not generate
the amide typically produced in the Staudinger ligation. Instead,
the phosphine coupling quickly occurs in high yield to provide
an O-methyl imidate linkage.28 Product analysis indicated the(A) 9-modiﬁed peptide to 10 and (B) 4-modiﬁed peptide to 12. Product peaks are
e states. The major peak denoted by a ( ) corresponds to 9 modiﬁed by HEPES.
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desired O-methyl imidate linkage, as the desired biotinylated pep-
tide was observed across multiple charge states (Fig. 5B).
3. Conclusion
In summary, the azide- and alkyne-functionalized N-mustard
analogs of SAM described here are demonstrated to be viable
cofactor mimics for PRMT1, as they are successfully transferred
to a model AcH4-21 peptide in an enzyme-dependent fashion.
Speciﬁcaly, azides 4–6 and alkyne 9 were identiﬁed to be the most
compatible with PRMT1 in generating the desired peptide prod-
ucts, as they exhibit higher relative abundances by LC MS com-
pared to azide 2 and alkynes 3, 7, and 8. Subsequent studies to
incorporate biological tags were carried out using click chemistry
and the Staudinger ligation with azide- and alkyne-modiﬁed
AcH4-21 peptides. Successful ligations were demonstrated to be
highly dependent on the yield of the enzyme-modiﬁed peptide
substrate, relative to unmodiﬁed peptide. Pivotal to pursuing
future studies examining the utility of 2–9 to function as novel bio-
chemical tools for studying protein methylation will be establish-
ing their efﬁcacy in being transferred to full-length protein, such
as histone H4, and incorporating biological tags to permit visual-
ization and isolation of modiﬁed proteins from complex mixtures.
We believe that this work paves a pathway to examine these novel
N-mustard SAM analogs with other protein methyltransferases,
including lysine methyltransferases, in the future.
4. Experimental
4.1. General
All reagents and solvents were purchased from commercial
sources and used without additional puriﬁcation. AcH4-21 peptide
was purchased from Peptide 2.0 and SAM from New England
Biolabs. PRMT1 was generously provided by Paul Thompson
(University of Massachusetts Medical School). N-Mustard SAM
analogs which have been previously synthesized were brought
up in 2.5 mM sulfuric acid and concentrations were determined
by UV/Vis measurement of optical density at 260 nm and Beer’s
law. The following molar extinction constants were used:
15400 M1 cm1 (for 1), 8900 M1 cm1 (for 2), 5735 M1 cm1
(for 3), 6633 M1 cm1 (for 4), 12380 M1 cm1 (for 5),
11523 M1 cm1 (for 6), 9710 M1 cm1 (for 7), 10970 M1 cm1
(for 8), 11270 M1 cm1 (for 9).12–15 Stock solutions were stored
at 80 C for up to two weeks.
4.2. High-resolution LC–ESI MS
Experiments were performed on an Accela Open UPLC coupled
to an LTQ Orbitrap XL mass spectrometer (Thermo Fisher
Scientiﬁc). Samples were prepared in 5% acetonitrile (ACN) to a
ﬁnal concentration of 10 lM peptide. Sample separation of a
10 lL injection utilized a C18 column (Thermo Fisher Scientiﬁc,
Hypersil Gold 50  2.1 mm, 1.9 lm) at a ﬂow rate of
0.2 mL min1, and a gradient system consisting of 0.1% formic acid
in ddH2O (solvent A) and 0.1% formic acid in ACN (solvent B). The
gradient was run beginning with 2% B and followed by a linear
increase to 90% over a 10 min period. Solvent returned to 2% B
and held for an additional 10 min. The mass spectrometer was
operated in positive electrospray ionization mode with a spray
voltage of 4.00 kV, a capillary temperature of 300 C, a sheath gas
ﬂow of 72, and scans were performed in the range of 300–
2000m/z with the resolution set to 30,000. Data was analyzed
and masses were extracted using Thermo Xcalibur 2.1 software.4.3. PRMT1-catalyzed peptide modiﬁcation using N-mustard
SAM analogs
AcH4-21 peptide (83 lM ﬁnal) and SAM/SAM analog (1.67 mM
ﬁnal) were pre-incubated at 37 C for 10 min in assay buffer
(50 mM HEPES pH 8.0, 50 mM NaCl, and 1 mM EDTA containing
either 0.5 mM DTT or no DTT). Reactions were initiated with the
addition of PRMT1 (3.87 lM ﬁnal) and incubated at 37 C for
20 min. Reaction samples were quenched with 5% ACN (10 lM
ﬁnal peptide concentration) and analyzed via LTQ Orbitrap XL
using the analysis method described in Section 4.2. Expected
masses were calculated using the monoisotopic mass of AcH4-21
peptide with the addition of each analog (via ring-opening of the
aziridinium intermediate).
4.4. Biotinylation of peptides via click chemistry
Analog modiﬁed AcH4-21 peptide was heated for 10 min at
95 C to denature the PRMT1. Biotin-azide 10 (12 mM ﬁnal) was
added to alkyne 9-modiﬁed peptide or Biotin-alkyne 1129
(12 mM ﬁnal) was added to azide 5- or 6-modiﬁed peptide, along
with CuSO4TBTA complex (8 mM CuSO4 and 12 mM TBTA pre-
complexed for 2–3 min). The reactions were initiated with the
addition of sodium ascorbate (23.44 mM ﬁnal) and were allowed
to proceed for 2 h at 37 C. Products were conﬁrmed by LTQ
Orbitrap XL using the analysis method described in Section 4.2.
4.5. Biotinylation of peptides via Staudinger ligation
Azidated AcH4-21 peptide was heated for 10 min at 95 C to
denature the PRMT1. Biotin-phosphine 1227 (1.47 mM ﬁnal) was
added to azide 4-modiﬁed peptide and incubated at 37 C for 2 h.
Product was conﬁrmed by LTQ Orbitrap XL using the analysis
method described in Section 4.2.
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